Search

Displaying results 3061 - 3070 of 10000 in total
  1. Drug

    Equine Botulinum Neurotoxin E Immune FAB2

    go.drugbank.com/drugs/DB13897
    Approved

    Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in adults and pediatric patients.

    Synonyms: Botulinum Neurotoxin E immune FAB2 (equine), BOTULINUM NEUROTOXIN E IMMUNE FAB2, EQUINE
  2. Drug

    Equine Botulinum Neurotoxin C Immune FAB2

    go.drugbank.com/drugs/DB13898
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in adults and pediatric patients.

  3. Drug

    Equine Botulinum Neurotoxin G Immune FAB2

    go.drugbank.com/drugs/DB13899
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.

  4. Drug

    Equine Botulinum Neurotoxin D Immune FAB2

    go.drugbank.com/drugs/DB13902
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.

  5. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions.

    Products: Esmolol Hydrochloride in Water, Esmolol Hydrochloride In Sodium Chloride
  6. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    FDA in December 2025, following Fast Track, Qualified Infectious Disease Product, and Priority Review designations.[L54743,L54803] … [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking

  7. Drug

    Ambrosia artemisiifolia pollen

    go.drugbank.com/drugs/DB10385
    Approved

    Ambrosia artemisiifolia pollen is mainly used in allergenic testing.

  8. Drug

    R1295

    go.drugbank.com/drugs/DB05122
    Experimental

    R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. … Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.

  9. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic … Food and Drug Administration approved Crysvita (burosumab) in April 2018.

  10. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required. … Droloxifene may have an effect on bone and breast tissue because it induces apoptosis.

    Categories: Compounds used in a research, industrial, or household setting